Potential strategies to develop novel treatments aim at targeting specific proteins and related pathways with demonstrated relevance to PD, e.g., alpha-synuclein (aSyn) that accumulates and aggregates in neurons of PD patients, contributing to cell degeneration.4 The gene discussed is SNCA; the disease is Parkinson disease.